• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness analysis: The missing factor in the management of HCC.

作者信息

Njei Basile, Yi Irvin, Strazzabosco Mario

机构信息

Liver Center, Digestive Disease Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.

出版信息

Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0178. doi: 10.1097/CLD.0000000000000178. eCollection 2024 Jan-Jun.

DOI:10.1097/CLD.0000000000000178
PMID:38860130
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11164007/
Abstract
摘要

相似文献

1
Cost-effectiveness analysis: The missing factor in the management of HCC.成本效益分析：肝癌管理中缺失的因素。
Clin Liver Dis (Hoboken). 2024 Jun 7;23(1):e0178. doi: 10.1097/CLD.0000000000000178. eCollection 2024 Jan-Jun.
2
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting.在加拿大环境下，基于个体数据的潜在治愈性和联合治疗肝癌的成本效益分析。
Cancer Med. 2017 Sep;6(9):2017-2033. doi: 10.1002/cam4.1119. Epub 2017 Aug 8.
3
Cost-effectiveness of liver cancer screening.肝癌筛查的成本效益分析。
Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):961-72. doi: 10.1016/j.bpg.2013.08.021. Epub 2013 Oct 4.
4
Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review.肝细胞癌：筛查的成本效益。系统评价。
Risk Manag Healthc Policy. 2012;5:49-54. doi: 10.2147/RMHP.S18677. Epub 2012 Jun 19.
5
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.丙型肝炎病毒感染和高级纤维化患者治疗后持续病毒学应答的肝细胞癌监测的成本效益。
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1840-1849.e16. doi: 10.1016/j.cgh.2018.12.018. Epub 2018 Dec 20.
6
Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.肝硬化肝细胞癌监测中非对比简化磁共振成像的成本效用分析。
Gut Liver. 2024 Jan 15;18(1):135-146. doi: 10.5009/gnl230089. Epub 2023 Aug 10.
7
Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.磁共振成像在肝硬化高危患者肝癌监测中具有成本效益。
Hepatology. 2019 Apr;69(4):1599-1613. doi: 10.1002/hep.30330. Epub 2019 Feb 25.
8
Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.在患者层面的成本效益分析中与随机临床试验一起处理缺失数据。
Appl Health Econ Health Policy. 2005;4(2):65-75. doi: 10.2165/00148365-200504020-00001.
9
Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India.印度肝细胞癌（HCC）监测计划的经济评价。
Hepatol Int. 2008 Jun;2(2):231-6. doi: 10.1007/s12072-008-9054-5. Epub 2008 Feb 27.
10
Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials.整体是否大于其部分之和？随机对照试验中缺失数据填补对经济评价的影响。
Eur J Health Econ. 2020 Jul;21(5):717-728. doi: 10.1007/s10198-020-01166-z. Epub 2020 Feb 27.

本文引用的文献

1
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.
2
Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma.根据统计方法的差异估计医疗支出：一项基于全国索赔数据库的肝细胞癌患者研究。
PLoS One. 2020 Aug 13;15(8):e0237316. doi: 10.1371/journal.pone.0237316. eCollection 2020.
3
Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.
美国肝细胞癌的流行病学、人文和经济负担：一项系统文献综述
Hepat Oncol. 2020 Jul 21;7(3):HEP27. doi: 10.2217/hep-2020-0024.
4
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.肝癌监测的成本效益：效益和危害评估。
Am J Gastroenterol. 2020 Oct;115(10):1642-1649. doi: 10.14309/ajg.0000000000000715.
5
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.仑伐替尼对比索拉非尼作为不可切除肝细胞癌一线治疗药物的成本效用分析。
Oncologist. 2020 Mar;25(3):e512-e519. doi: 10.1634/theoncologist.2019-0501. Epub 2019 Nov 20.
6
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.仑伐替尼治疗不可切除肝细胞癌（uHCC）与索拉非尼在日本的成本效果分析。
J Gastroenterol. 2019 Jun;54(6):558-570. doi: 10.1007/s00535-019-01554-0. Epub 2019 Feb 20.
7
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.索拉非尼经导管动脉化疗栓塞与单纯经导管动脉化疗栓塞治疗不可切除肝细胞癌的成本效果分析。
Hepatobiliary Pancreat Dis Int. 2017 Oct 15;16(5):493-498. doi: 10.1016/S1499-3872(17)60009-2.
8
Value-based care in hepatology.肝科学中的价值医疗。
Hepatology. 2017 May;65(5):1749-1755. doi: 10.1002/hep.29042.
9
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.索拉非尼与立体定向体部放疗治疗不可切除的晚期肝细胞癌的成本效益
Radiat Oncol. 2016 May 18;11:69. doi: 10.1186/s13014-016-0644-4.
10
Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.有效但昂贵：如何应对评估肝病改善健康技术中的困难权衡。
Hepatology. 2016 Oct;64(4):1331-42. doi: 10.1002/hep.28527. Epub 2016 Apr 4.